A Comparison of the Dexamethasone Implant (Ozurdex®) and Inferior Fornix-Based Sub-Tenon Triamcinolone Acetonide for Treatment of Inflammatory Ocular Diseases

References

• Rothova A, Suttorp-Van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332–336.
   PubMed Web of Science ®Google Scholar
• Tomkins-Netzer O, Talat L, Bar A, et al. Long-term clinical outcome and causes of vision loss in patients with uveitis. Ophthalmology. 2014;121(8):2387–2392.
   PubMedGoogle Scholar
• Lafranco Dafflon M, Tran VT, Guex-Crosier Y, Herbort CP. Posterior sub-Tenon steroid injections for the treatment of posterior ocular inflammation: indications, efficacy and side effects. Graefes Arch Clin Exp Ophthalmol. 1999;237:289–295.
   PubMed Web of Science ®Google Scholar
• Okada AA, Wakabayashi T, Morimura Y, et al. Trans-Tenon’s retrobulbar triamcinolone infusion for the treatment of uveitis. Br J Ophthalmol. 2003;87:968–971.
   PubMed Web of Science ®Google Scholar
• Bae JH, Lee CS, Lee SC. Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema. Retina. 2011;31(1):111–118. doi:10.1097/IAE.0b013e3181e378af.
   PubMed Web of Science ®Google Scholar
• Ozdek S, Bahceci UA, Gurelik G, Hasanreisoglu B. Posterior sub-Tenon and intravitreal triamcinolone acetonide for diabetic macular edema. J Diabetes Complications. 2006;20:246–251.
   PubMed Web of Science ®Google Scholar
• Inoue M, Takeda K, Morita K, Yamada M, Tanigawara Y, Oguchi Y. Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or sub-Tenon injection. Am J Ophthalmol. 2004;38:1046–1048.
   Google Scholar
• Hunter RS, Lobo AM. Dexamethasone intravitreal implant for the treatment of noninfectious uveitis. Clin Ophthalmol. 2011;5:1613–1621. doi:10.2147/OPTH.S17419.
   PubMedGoogle Scholar
• London NJ, Chiang A, Haller JA. The dexamethasone drug delivery system: indications and evidence. Adv Ther. 2011;28(5):351–366. doi:10.1007/s12325-011-0019-z.
   PubMed Web of Science ®Google Scholar
• Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52(1):80–86. doi:10.1167/iovs.10-5285.
   PubMed Web of Science ®Google Scholar
• Williams GA, Haller JA, Kuppermannn BD, et al. Dexamethasone DDS Phase II Study Group. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol. 2009;147(6):1048–1054.
   PubMed Web of Science ®Google Scholar
• Lowder C, Belfort R Jr, Lightman S, et al. Ozurdex HURON Study Group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129(5):545–553. doi:10.1001/archophthalmol.2010.339.
   PubMed Web of Science ®Google Scholar
• Mayer WJ, Kurz S, Wolf A, et al. Dexamethasone implant as an effective treatment option for macular edema due to Irvine-Gass syndrome. J Cataract Refract Surg. 2015;41(9):1954–1956.
   PubMed Web of Science ®Google Scholar
• Zarranz-Ventura J, Carreño E, Johnston RL, et al. Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency. Am J Ophthalmol. 2014;158(6):1136–1145.e5. doi:10.1016/j.ajo.2014.09.003.
   PubMed Web of Science ®Google Scholar
• Khurana RN, Porco TC. Efficacy and safety of dexamethasone intravitreal implant for persistent uveitis cystoid macular edema. Retina. 2015;35(7):1640–1646. doi:10.1001/jamaophthalmol.2017.1815.
   PubMed Web of Science ®Google Scholar
• Cao JH, Mulvalhill M, Zhang L, Joondeph BC, Dacey MS. Dexamethasone intravitreal implant in the treatment of persistent uveitis macular edema in the absence of active inflammation. Ophthalmology. 2014;121(10):1871–1876. doi:10.1016/j.ophtha.2014.04.012.
   PubMed Web of Science ®Google Scholar
• Bratton ML, He YG, Weakley DR. Dexamethasone intravitreal implant (Ozurdex) for the treatment of pediatric uveitis. J AAPOS. 2014;18(2):110–113. doi:10.1016/j.jaapos.2013.11.014.
   PubMed Web of Science ®Google Scholar
• Tomkins-Netzer O, Taylor SR, Bar A, et al. Treatment with repeat dexamethasone implants results in long-term disease control in eyes with noninfectious uveitis. Ophthalmology. 2014;121(8):1649–1654. doi:10.1016/j.ophtha.2014.02.003.
   PubMed Web of Science ®Google Scholar
• Adan A, Pelegrin L, Rey A, et al. Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients. Retina. 2013;33(7):1435–1440. doi:10.1097/IAE.0b013e31827e247b.
   PubMed Web of Science ®Google Scholar
• Arcinue CA, Ceron OM, Foster CS. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther. 2013;29(5):501–507. doi:10.1089/jop.2012.0180.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140:509–516.
   PubMed Web of Science ®Google Scholar
• Sugar EA, Jabs DA, Altaweel MM, et al. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Identifying a clinically meaningful threshold for change in uveitic macular edema evaluated by optical coherence tomography. Am J Ophthalmol. 2011;152(6):1044–1052.e5.
   PubMed Web of Science ®Google Scholar
• Byun YS, Park YH. Complications and safety profile of posterior subtenon injection of triamcinolone acetonide. J Ocul Pharmacol Ther. 2009;5(2):159–162. doi:10.1089/jop.2008.0087.
   Google Scholar
• Baath J, Ells AL, Crichton A, Kherani A, Williams RG. Safety profile of intravitreal triamcinolone acetonide. J Ocul Pharmacol Ther. 2007;23:304–310.
   PubMed Web of Science ®Google Scholar